Champions Oncology announced the full commercial launch of its radiopharmaceutical services platform on July 8, 2025. This expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models.
This milestone follows the company's recent expansion of its radioactive materials license and the completion of its radiochemistry infrastructure. Champions Oncology has also successfully screened more than thirty PDX models in collaboration with pharmaceutical and biotech partners.
The new platform is expected to be a high-margin business, with projected gross margins of 50% to 60%. This launch positions Champions Oncology in a high-demand field currently experiencing capacity constraints, providing a significant growth opportunity for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.